TY - JOUR
T1 - Small cell lung cancer
T2 - Will recent progress lead to improved outcomes?
AU - Pietanza, M. Catherine
AU - Byers, Lauren Averett
AU - Minna, John D.
AU - Rudin, Charles M.
N1 - Publisher Copyright:
© 2015 American Association for Cancer Research.
PY - 2015/5/15
Y1 - 2015/5/15
N2 - Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with a unique natural history characterized by a short doubling time, high growth fraction, and early development of widespread metastases. Although a chemotherapy- and radiationsensitive disease, SCLC typically recurs rapidly after primary treatment, with only 6% of patients surviving 5 years from diagnosis. This disease has been notable for the absence of major improvements in its treatment: Nearly four decades after the introduction of a platinum etoposide doublet, therapeutic options have remained virtually unchanged, with correspondingly little improvement in survival rates. Here, we summarize specific barriers and challenges inherent to SCLC research and care that have limited progress in novel therapeutic development to date. We discuss recent progress in basic and translational research, especially in the development of mouse models, which will provide insights into the patterns of metastasis and resistance in SCLC. Opportunities in clinical research aimed at exploiting SCLC biology are reviewed, with an emphasis on ongoing trials. SCLC has been described as a recalcitrant cancer, for which there is an urgent need for accelerated progress. The NCI convened a panel of laboratory and clinical investigators interested in SCLC with a goal of defining consensus recommendations to accelerate progress in the treatment of SCLC, which we summarize here.
AB - Small cell lung cancer (SCLC) is an aggressive neuroendocrine malignancy with a unique natural history characterized by a short doubling time, high growth fraction, and early development of widespread metastases. Although a chemotherapy- and radiationsensitive disease, SCLC typically recurs rapidly after primary treatment, with only 6% of patients surviving 5 years from diagnosis. This disease has been notable for the absence of major improvements in its treatment: Nearly four decades after the introduction of a platinum etoposide doublet, therapeutic options have remained virtually unchanged, with correspondingly little improvement in survival rates. Here, we summarize specific barriers and challenges inherent to SCLC research and care that have limited progress in novel therapeutic development to date. We discuss recent progress in basic and translational research, especially in the development of mouse models, which will provide insights into the patterns of metastasis and resistance in SCLC. Opportunities in clinical research aimed at exploiting SCLC biology are reviewed, with an emphasis on ongoing trials. SCLC has been described as a recalcitrant cancer, for which there is an urgent need for accelerated progress. The NCI convened a panel of laboratory and clinical investigators interested in SCLC with a goal of defining consensus recommendations to accelerate progress in the treatment of SCLC, which we summarize here.
UR - http://www.scopus.com/inward/record.url?scp=84941986957&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84941986957&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-14-2958
DO - 10.1158/1078-0432.CCR-14-2958
M3 - Article
C2 - 25979931
AN - SCOPUS:84941986957
SN - 1078-0432
VL - 21
SP - 2244
EP - 2255
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 10
ER -